Sinda Biologics (01801.HK) announced a recent collaboration with Wecomput to jointly advance the construction of the Shinda Bio National Building Computing Platform to accelerate the drug R&D process by building a one-stop AI drug R&D platform that is efficient, easy to use, digitized, intelligent and automated, REDUCE AI GROUNDBREAKING AND EXPERIMENTAL COSTS, SHORTEN DRUG R&D CYCLES, AND IMPROVE R&D SUCCESS RATES TO BRING MORE INNOVATIVE DRUGS AND TREATMENT SOLUTIONS TO PATIENTS.
信達生物(01801.HK)與唯信計算達成AI藥物研發平台建設合作
Innovent Bio (01801.HK) has reached a cooperation with Insilico Medicine to establish an AI drug R&D platform.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.